Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and cancer1. Cell entry of HCV2 and other pathogens3,4,5 is mediated by tight junction (TJ) proteins, but successful therapeutic targeting of TJ proteins has not been reported yet. Using a human liver–chimeric mouse model6, we show that a monoclonal antibody specific for the TJ protein claudin-1 (ref. 7) eliminates chronic HCV infection without detectable toxicity. This antibody inhibits HCV entry, cell-cell transmission and virus-induced signaling events. Antibody treatment reduces the number of HCV-infected hepatocytes in vivo, highlighting the need for de novo infection by means of host entry factors to maintain chronic infection. In summary, we demonstrate that an antibody targeting a virus receptor can cure chronic viral infection and uncover TJ proteins as targets for antiviral therapy.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $20.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
This work was supported by the European Union (ERC-2008-AdG-233130-HEPCENT, ERC-2010-StG-260767-ncRNAVIR, INTERREG-IV-Rhin Supérieur-FEDER-Hepato-Regio-Net 2009 and 2012), ANRS (ANRS 2009/183, 2009/136, 2011/132, 2012/239, 2013/108), ANR (Laboratoires d'excellence ANR-10-LABX-0028_HEPSYS and ANR-10-LABX-36 netRNA), Fondation ARC pour la recherche (NanoISI and TheraHCC IHUARC IHU201301187), Institut Hospitalo-Universitaire (IHU) Strasbourg, the Wilhelm Sander Foundation, Région Alsace, Institut National du Cancer, the Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Strasbourg, the Ghent University (GOA 01G01712) and the Research Foundation—Flanders (projects 1500910N and G052112N). We are grateful to S. Ito (Harvard Medical School) for electron microscopy studies, F.-L. Cosset (Inserm U1111, ENS Lyon, France) and J. Ball (University of Nottingham, Nottingham, UK) for retroviral vectors for HCVpp production, F. Chisari (The Scripps Research Institute, La Jolla, CA, USA) for the gift of Huh7.5.1 cells, A. Patel (MRC Virology Unit, Glasgow, UK) for E2-specific mAb AP33 and Huh7.5-GFP cells, S. Foung (Stanford Blood Center, Palo Alto, CA, USA) for E2-specific mAb CHB-23 and C.M. Rice and M. Evans (Rockefeller University and Mount Sinai School of Medicine, New York) for providing human and mouse CLDN1 expression constructs as well as Huh7.5 cells. We acknowledge S. Durand, L. Heydmann, E. Soulier, J. Barths, N. Brignon, S. Pernot (Inserm U1110, Strasbourg), O. Wendling and N. Messadeq (Institut Clinique de la Souris - ICS, Illkirch), C. Valencia (PCBIS, Illkirch), S. Kallis (University of Heidelberg, Germany) for technical work, F. Grunert and J. Thompson (Aldevron, Freiburg) for helpful discussions, H. Jacob and M.F. Champy (ICS, Illkirch) for histopathological, hematological and biochemical analyzes, P. Bachellier (Strasbourg University Hospitals) for providing liver resections for isolation of primary human hepatocytes, the Laboratoire Schuh—groupement Bio67, Strasbourg and the Plateau Technique de Microbiologie, Laboratoire de Virologie (S. Fafi-Kremer and F. Stoll-Keller), University Hospital Strasbourg for performing viral load analyses, and the IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire) microarray and sequencing platform, member of the France Génomique program, for the sequencing of our libraries. Part of the animal experiments was carried out within the small animal exploration facility Cardiex (Nantes), which is supported by the GIS-IBiSA (Groupement d'Intérêt Scientifique – Infrastructure en Biologie Santé et Agronomie) program.
Supplementary Figures 1–15 and Supplementary Tables 1–5
About this article
Medicinal Research Reviews (2019)